Sorafenib, the first Food and Drug Administration (FDA)-approved multi-kinase inhibitor for metastatic ccRCC (253), was initially shown to induce ferroptosis by inhibiting SLC7A11 (254). Here, SLC7A11 is linked to nonpapillary renal cell carcinoma.